This company has been marked as potentially delisted and may not be actively trading. NYSE:MRX Medicis Pharmaceutical (MRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesOptions ChainOwnershipTrendsBuy This Stock About Medicis Pharmaceutical Stock (NYSE:MRX) 30 days 90 days 365 days Advanced Chart Remove Ads Get Medicis Pharmaceutical alerts:Sign Up Key Stats Today's Range$32.54▼$33.3350-Day Range N/A52-Week Range$18.13▼$40.05Volume415,945 shsAverage Volume381,702 shsMarket Capitalization$2.69 billionP/E RatioN/ADividend Yield1.46%Price Target$35.00Consensus RatingModerate Buy Company OverviewMedicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).Read More… Remove Ads Medicis Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreMRX MarketRank™: Medicis Pharmaceutical scored higher than 14% of companies evaluated by MarketBeat, and ranked 909th out of 939 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingMedicis Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMedicis Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medicis Pharmaceutical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-0.34% Earnings GrowthEarnings for Medicis Pharmaceutical are expected to decrease by -0.34% in the coming year, from $2.94 to $2.93 per share. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MRX. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldMedicis Pharmaceutical pays a meaningful dividend of 1.44%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthMedicis Pharmaceutical does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Medicis Pharmaceutical will have a dividend payout ratio of 19.11% next year. This indicates that Medicis Pharmaceutical will be able to sustain or increase its dividend.Read more about Medicis Pharmaceutical's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MRX. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Medicis Pharmaceutical this week, compared to 0 articles on an average week.Search InterestOnly 7 people have searched for MRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Medicis Pharmaceutical to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medicis Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.79% of the stock of Medicis Pharmaceutical is held by insiders.Read more about Medicis Pharmaceutical's insider trading history. Receive MRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address MRX Stock News HeadlinesMarex Group plc provides preliminary Q1 results range and hosts Investor Day in New YorkApril 2 at 7:05 AM | globenewswire.comMarex Group plc Provides Details for Upcoming Investor Day on April 2, 2025March 24, 2025 | globenewswire.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 3, 2025 | Weiss Ratings (Ad)Marex Group plc announces record fourth quarter and full year 2024 resultsMarch 6, 2025 | globenewswire.comMarex Group plc to Announce Fourth Quarter and Full Year 2024 Results on March 6, 2025 with an Investor Day on April 2, 2025February 17, 2025 | globenewswire.comMicuRx Pharmaceuticals: FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM InfectionsFebruary 2, 2025 | finanznachrichten.deMarex Group plc Announces Third Quarter 2024 ResultsNovember 7, 2024 | globenewswire.comMarex Group plc Announces Pricing of the Public OfferingOctober 24, 2024 | globenewswire.comSee More Headlines MRX Stock Analysis - Frequently Asked Questions How were Medicis Pharmaceutical's earnings last quarter? Medicis Pharmaceutical Corp (NYSE:MRX) posted its earnings results on Thursday, March, 6th. The healthcare company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.12. When did Medicis Pharmaceutical IPO? Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering on Thursday, April 25th 2024. The company issued 15,384,615 shares at $19.00 per share. What other stocks do shareholders of Medicis Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicis Pharmaceutical investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings3/06/2025Record date for 3/31 Dividend3/17/2025Ex-Dividend for 3/31 Dividend3/17/2025Dividend Payable3/31/2025Today4/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorFinance Industry Security & commodity brokers, dealers, exchanges & services Sub-IndustryN/A Current SymbolNYSE:MRX CIK859368 Webwww.Medicis.com Phone+1-212-5992000FaxN/AEmployees2,074Year FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$43.00 Low Stock Price Target$24.00 Potential Upside/Downside-8.7%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.18 Current Ratio1.04 Quick Ratio1.08 Sales & Book Value Annual Sales$1.24 billion Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares70,290,000Free Float67,627,000Market Cap$2.69 billion OptionableOptionable BetaN/A A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NYSE:MRX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicis Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicis Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.